Investors in Exelixis Inc (Symbol: EXEL) saw new options become available this week, for the November 21st expiration. One of the key inputs that goes into the price an option buyer is willing to ...

so it seems like value investors will conclude that EXEL is the superior option right now. To read this article on Zacks.com click here.

In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other most profitable biotech stocks to buy right now. With improved market conditions ...

In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other most profitable biotech stocks to buy right now. With improved market conditions ...

Explore Exelixis stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for EXEL. FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In ...

Obviously, there is little we can say about the cross-trial comparison, but it does underscore how challenging this space is, and EXEL has a real shot to add an important option to refractory CRC ...

In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other best biotech ... should clinical studies be successful, offer an “option-like structure,” even ...

Another notable valuation metric for EXEL is its P/B ratio of 4.54. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities.